IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA

Cardiac events in stage III NSCLC treated in daily clinical practice

Ceritinib and ribociclib in ALK-positive NSCLC

Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC

Therapeutic targeting at a pre-metastatic stage for brain metastases from lung cancer

SPLENDOUR: Added denosumab in first line adv NSCLC treatment

IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy

ESMO 2018: Highlights

Advances in metastatic non small cell lung cancer

KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC